USGrantedMethod of treatment

Intranasal esketamine dosing regimen for treatment-resistant depression

US-10869844-B2

Bibliographic data

Patent number: US-10869844-B2
Jurisdiction: US
Status: Granted
Type: Method of treatment
Priority date: 15 September 2014
Filing date: 26 December 2019
Grant date: 22 December 2020

Compounds claimed

Arylcyclohexylamine

Assignees

Johnson & Johnson

Johnson & Johnson is a publicly traded global healthcare company rather than a venture fund or dedicated asset manager. Its business spans pharmaceuticals and medical technology, and the company is based in New Brunswick, New Jersey, United States. In the psychedelic ecosystem, Johnson & Johnson matters mainly through its neuroscience and psychiatry-adjacent pharmaceutical activity rather than as a standalone investor. Its acquisition of Intra-Cellular Therapies, a CNS-focused biopharma, shows continued interest in neuropsychiatric therapeutics and related clinical-stage assets.

Prior art & evidence

Prior art and related research that speaks to this patent, curated from the Blossom database.

Related research

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (TRANSFORM-3)

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: data from the enTRD registry

Analysis

Esketamine, the S-enantiomer of ketamine, became the first genuinely novel-mechanism antidepressant approved in decades when Spravato cleared the FDA in 2019.

Racemic ketamine is old and generic, but the single enantiomer and its intranasal delivery gave Johnson & Johnson a defensible position, layered into a sizeable Orange Book patent thicket. The trials linked here trace the clinical programme that built the case for it.